Patents by Inventor Paul Lyne

Paul Lyne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10319981
    Abstract: A battery balancing system for parallel connected batteries for balancing batteries that are at dissimilar voltages. The system has first and second buses, connected by a current limiter. A high bus takes energy from the highest voltage battery or batteries in the system and transfers the energy through the current limiter to the low bus, which in turn delivers energy to the lowest voltage battery or batteries in the system.
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: June 11, 2019
    Assignee: Revision Military S.a.r.L.
    Inventors: Steve Carkner, Eric John Georges Andrasi, Paul Lynes
  • Publication number: 20170244092
    Abstract: A battery balancing system for parallel connected batteries for balancing batteries that are at dissimilar voltages. The system has first and second buses, connected by a current limiter. A high bus takes energy from the highest voltage battery or batteries in the system and transfers the energy through the current limiter to the low bus, which in turn delivers energy to the lowest voltage battery or batteries in the system.
    Type: Application
    Filed: February 23, 2017
    Publication date: August 24, 2017
    Applicant: Revision Military S.a.r.L.
    Inventors: Steve Carkner, Eric John Georges Andrasi, Paul Lynes
  • Patent number: 8835465
    Abstract: This invention relates to novel compounds having the formula (I): and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: September 16, 2014
    Assignee: AstraZeneca AB
    Inventors: Audrey Molina, Michelle Lamb, Paul Lyne, Peter Mohr, Bin Wang, Tao Wang, Dingwei Yu
  • Patent number: 8324252
    Abstract: This invention relates to novel compounds having the Formula (I) to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.
    Type: Grant
    Filed: February 1, 2006
    Date of Patent: December 4, 2012
    Assignee: Astrazeneca AB
    Inventors: Audrey Davies, Michelle Lamb, Paul Lyne, Tao Wang, Dingwei Yu, Peter Mohr, Bin Wang
  • Publication number: 20100216791
    Abstract: The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B-Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.
    Type: Application
    Filed: August 15, 2007
    Publication date: August 26, 2010
    Applicant: ASTRAZENECA
    Inventors: Brian Aquila, Donald J. Cook, Craig Johnstone, Stephen Lee, Paul Lyne, David Alan Rudge, Melissa Vasbinder, Haixia Wang
  • Publication number: 20100105714
    Abstract: The invention features compounds of the general Formula (I): (formula should be inserted here) Compounds of Formula (I) possess unexpectedly high affinity for Alk5 and/or Alk4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders.
    Type: Application
    Filed: January 30, 2008
    Publication date: April 29, 2010
    Applicant: Biogen Idec MA Inc.
    Inventors: Lihong Sun, Wen-Cherng Lee, Paul Lyne
  • Patent number: 7691865
    Abstract: Compounds of formula I possess unexpectedly high affinity for Alk 5 and/or Alk 4, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including fibrotic disorders.
    Type: Grant
    Filed: September 5, 2003
    Date of Patent: April 6, 2010
    Assignee: Biogen Idec MA Inc.
    Inventors: Wen-Cherng Lee, Mary Beth Carter, Lihong Sun, Paul Lyne, Claudio Chuaqui, Zhongli Zheng, Juswinder Singh, Paula Boriack-Sjodin
  • Publication number: 20100029643
    Abstract: The invention relates to chemical compounds of formula (I), (Ia) and (Ib) or pharmaceutically acceptable salts thereof, which possess Edg-1 antagonistic activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an anti-cancer effect in a warm-blooded animal, such as man.
    Type: Application
    Filed: November 8, 2007
    Publication date: February 4, 2010
    Applicant: ASTRAZENECA AB
    Inventors: Gurmit Grewal, Edward Hennessy, Victor Kamhi, Danyang Li, Paul Lyne, Vibha Oza, Jamal Carlos Saeh, Qibin Su, Bin Yang
  • Publication number: 20090275570
    Abstract: The invention relates to novel compounds of Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds possess CHK1 kinase inhibitory activity, PDK1 inhibitory activity and Pak kinase inhibitory activity and are accordingly useful in the treatment and/or prophylaxis of cancer.
    Type: Application
    Filed: April 5, 2006
    Publication date: November 5, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Kevin Daly, Nicola Heron, Alexander Hird, Stephanos Ioannidis, James Janetka, Paul Lyne, Jaime Scott, Dorin Toader, Melissa Vasbinder, Dingwei Yu, Yan Yu
  • Publication number: 20090227648
    Abstract: This invention relates to novel compounds having the formula and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.
    Type: Application
    Filed: April 20, 2005
    Publication date: September 10, 2009
    Inventors: Paul Lyne, Bin Wang
  • Publication number: 20090170849
    Abstract: The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.
    Type: Application
    Filed: April 4, 2007
    Publication date: July 2, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Brian Aquila, Paul Lyne, Timothy Pontz
  • Publication number: 20090163525
    Abstract: The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.
    Type: Application
    Filed: April 4, 2007
    Publication date: June 25, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Brian A. Aquila, Paul Lyne, Timothy Pontz
  • Publication number: 20090149484
    Abstract: The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B-Raf inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
    Type: Application
    Filed: April 17, 2007
    Publication date: June 11, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Brian Aquila, Paul Lyne, Timothy Pontz
  • Publication number: 20090118261
    Abstract: The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.
    Type: Application
    Filed: August 26, 2005
    Publication date: May 7, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Brian Aquila, Leslie Dakin, Jayachandran Ezhuthachan, Stephen Lee, Paul Lyne, Timothy Pontz, XiaoLan Zheng
  • Publication number: 20090092601
    Abstract: Humanized antibodies to LT-?-R and methods of use thereof are provided.
    Type: Application
    Filed: June 30, 2008
    Publication date: April 9, 2009
    Applicant: Biogen Idec MA Inc.
    Inventors: Ellen Garber, Paul Lyne, Jose William Saldanha
  • Publication number: 20090054396
    Abstract: This invention relates to novel compounds having the structural formula (I) and to their pharmaceutical salts, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cancer.
    Type: Application
    Filed: September 8, 2008
    Publication date: February 26, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Susan Ashwell, Thomas Gero, Stephanos Ioannidis, James Janetka, Paul Lyne, Vibha Oza, Mei Su, Dingwei Yu, Stephanie Springer
  • Publication number: 20090054469
    Abstract: The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.
    Type: Application
    Filed: August 28, 2005
    Publication date: February 26, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Brian Aquila, Paul Lyne, Timothy Pontz
  • Publication number: 20080312206
    Abstract: The invention relates to chemical compounds, or pharmaceutically acceptable salts thereof of the formula which possess CSF 1R kinase inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.
    Type: Application
    Filed: December 19, 2006
    Publication date: December 18, 2008
    Applicant: AstraZeneca AB
    Inventors: Brian Aquila, Donald Cook, Leslie Dakin, Stephanos Ioannidis, Paul Lyne, David Scott, Xiaolan Zheng
  • Publication number: 20080306096
    Abstract: The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.
    Type: Application
    Filed: December 19, 2006
    Publication date: December 11, 2008
    Applicant: ASTRAZENECA AB
    Inventors: Brian Aquila, Jayachandran Ezhuthachan, Paul Lyne, Timothy Pontz, Xiaolan Zheng
  • Publication number: 20080275022
    Abstract: The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.
    Type: Application
    Filed: June 14, 2005
    Publication date: November 6, 2008
    Applicant: AstraZeneca AB
    Inventors: Brian Aquila, Les Dakin, Jayachandran Ezhuthachan, John Lee, Paul Lyne, Timothy Pontz